DE3687575T2 - Verwendung von 6-methylen-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphin. - Google Patents
Verwendung von 6-methylen-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphin.Info
- Publication number
- DE3687575T2 DE3687575T2 DE8686906052T DE3687575T DE3687575T2 DE 3687575 T2 DE3687575 T2 DE 3687575T2 DE 8686906052 T DE8686906052 T DE 8686906052T DE 3687575 T DE3687575 T DE 3687575T DE 3687575 T2 DE3687575 T2 DE 3687575T2
- Authority
- DE
- Germany
- Prior art keywords
- hydroxydihydronormorphine
- cyclopropylmethyl
- methylene
- deoxy
- opioid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000001356 surgical procedure Methods 0.000 claims description 13
- 229960002428 fentanyl Drugs 0.000 claims description 11
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims description 11
- 230000036592 analgesia Effects 0.000 claims description 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 8
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000002405 diagnostic procedure Methods 0.000 claims description 5
- 229960005181 morphine Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229960000482 pethidine Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000003533 narcotic effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 20
- 230000008485 antagonism Effects 0.000 abstract description 14
- 238000002347 injection Methods 0.000 abstract description 8
- 239000007924 injection Substances 0.000 abstract description 8
- 230000002035 prolonged effect Effects 0.000 abstract description 4
- 230000000069 prophylactic effect Effects 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 230000000246 remedial effect Effects 0.000 abstract 1
- 230000003444 anaesthetic effect Effects 0.000 description 27
- 229960004127 naloxone Drugs 0.000 description 16
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 229940005483 opioid analgesics Drugs 0.000 description 11
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 9
- 206010038678 Respiratory depression Diseases 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000000014 opioid analgesic Substances 0.000 description 9
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 8
- 229960005297 nalmefene Drugs 0.000 description 8
- 239000003401 opiate antagonist Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 229940080861 demerol Drugs 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 238000002690 local anesthesia Methods 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 101100243025 Arabidopsis thaliana PCO2 gene Proteins 0.000 description 2
- 208000003870 Drug Overdose Diseases 0.000 description 2
- 206010033296 Overdoses Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 231100000725 drug overdose Toxicity 0.000 description 2
- 238000001839 endoscopy Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000003887 narcotic antagonist Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940124636 opioid drug Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LBCZKDPFDXFDTN-GGNLRSJOSA-N 6-methylenedihydrodesoxymorphine Chemical compound O([C@H]1C(CC[C@H]23)=C)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O LBCZKDPFDXFDTN-GGNLRSJOSA-N 0.000 description 1
- 241000609730 Antidorcas marsupialis Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000282985 Cervus Species 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 206010023204 Joint dislocation Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 241000283868 Oryx Species 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical class C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940052318 opioid anesthetics Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000037325 pain tolerance Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229940124547 specific antidotes Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007627 surgical diagnostic procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77321385A | 1985-09-06 | 1985-09-06 | |
| PCT/US1986/001847 WO1987001282A2 (en) | 1985-09-06 | 1986-09-08 | Method and composition for providing sustained opioid antagonism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3687575D1 DE3687575D1 (de) | 1993-03-04 |
| DE3687575T2 true DE3687575T2 (de) | 1993-07-01 |
Family
ID=25097554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8686906052T Expired - Lifetime DE3687575T2 (de) | 1985-09-06 | 1986-09-08 | Verwendung von 6-methylen-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphin. |
| DE19863690457 Withdrawn DE3690457T1 (enExample) | 1985-09-06 | 1986-09-08 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19863690457 Withdrawn DE3690457T1 (enExample) | 1985-09-06 | 1986-09-08 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0236477B1 (enExample) |
| JP (1) | JPS63500799A (enExample) |
| AT (1) | ATE84717T1 (enExample) |
| DE (2) | DE3687575T2 (enExample) |
| WO (1) | WO1987001282A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200001942T2 (tr) | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid agonist/antagonist kombinasyonlar |
| SI2283842T1 (sl) | 2000-02-08 | 2015-07-31 | Euro-Celtique S.A. | Oralne formulacije opioidnih agonistov, varne pred zlorabo |
| EP1387673B1 (en) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Abuse-resistant controlled-release opioid dosage form |
| ES2326794T3 (es) | 2001-08-06 | 2009-10-20 | Euro-Celtique S.A. | Formulaciones de agonistas opioides con antagonista liberable y secuestrado. |
| LT2425821T (lt) | 2002-04-05 | 2017-07-25 | Euro-Celtique S.A. | Farmacinis preparatas, turintis oksikodono ir naloksono |
| SI1551372T1 (en) | 2002-09-20 | 2018-08-31 | Alpharma Pharmaceuticals Llc | SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES |
| TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
| EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
| SI2484346T1 (sl) | 2006-06-19 | 2017-05-31 | Alpharma Pharmaceuticals Llc | Farmacevtski sestavki |
| US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| PL2405915T3 (pl) | 2009-03-10 | 2019-05-31 | Euro Celtique Sa | Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson |
| KR20160034352A (ko) | 2013-07-23 | 2016-03-29 | 유로-셀티큐 에스.에이. | 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB769517A (en) * | 1953-10-20 | 1957-03-06 | Merck & Co Inc | Analgesic compositions |
| US3493657A (en) * | 1961-03-14 | 1970-02-03 | Mozes Juda Lewenstein | Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine |
| US3814768A (en) * | 1971-11-26 | 1974-06-04 | Lewenstein E | 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts |
| US4322426A (en) * | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
| WO1983003197A1 (en) * | 1982-03-16 | 1983-09-29 | Univ Rockefeller | Method for controlling gastrointestinal dysmotility |
| US4567185A (en) * | 1983-05-13 | 1986-01-28 | Key Pharmaceuticals, Inc. | Endorphin blockage |
| US4535157A (en) * | 1983-11-01 | 1985-08-13 | Key Pharmaceuticals, Inc. | Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone |
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
-
1986
- 1986-09-08 AT AT86906052T patent/ATE84717T1/de not_active IP Right Cessation
- 1986-09-08 JP JP61505302A patent/JPS63500799A/ja active Pending
- 1986-09-08 WO PCT/US1986/001847 patent/WO1987001282A2/en not_active Ceased
- 1986-09-08 EP EP86906052A patent/EP0236477B1/en not_active Expired - Lifetime
- 1986-09-08 DE DE8686906052T patent/DE3687575T2/de not_active Expired - Lifetime
- 1986-09-08 DE DE19863690457 patent/DE3690457T1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE3687575D1 (de) | 1993-03-04 |
| WO1987001282A2 (en) | 1987-03-12 |
| WO1987001282A3 (en) | 1987-08-13 |
| EP0236477A1 (en) | 1987-09-16 |
| JPS63500799A (ja) | 1988-03-24 |
| ATE84717T1 (de) | 1993-02-15 |
| EP0236477B1 (en) | 1993-01-20 |
| DE3690457T1 (enExample) | 1987-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60009346T2 (de) | Buprenorphin enthaltende analgetische zusammensetzungen | |
| DE60126265T2 (de) | Zusammensetzung bestehend aus Phentolaminmesylat und deren Verwendung | |
| DE69806246T2 (de) | Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika | |
| DE69523295T2 (de) | Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung | |
| Grubb et al. | Comparison of lidocaine, xylazine, and xylazine/lidocaine for caudal epidural analgesia in horses | |
| DE69012591T2 (de) | Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen. | |
| DE69734006T2 (de) | Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonisten | |
| DE69814917T2 (de) | Transdermale therapeutische vorrichtung mit capsaicin und seinen analogen | |
| DE69017596T2 (de) | Verwendung eines Opiatantagonisten zur Herstellung eines transdermal zu verabreichenden Arzneimittels sowie eine Vorrichtung zur transdermalen Verabreichung. | |
| DE3218761C2 (enExample) | ||
| DE69231792T2 (de) | Verfahren zur aufhebung der lokalanästhesie und reaktionssystem dafür | |
| DE10197266T5 (de) | Verfahren zur örtlichen Betäubung und Schmerzstillung | |
| AU2001259848A1 (en) | Local anesthetic methods and kits | |
| EP1353659A1 (de) | Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen | |
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| ADAMS et al. | The local anesthetic activity of tetrodotoxin alone and in combination with vasoconstrictors and local anesthetics | |
| EP0236477B1 (en) | Use of 6-methylene-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphine | |
| DE69209140T2 (de) | Verwendung Glycine/NMDA-Rezeptorliganden zur Herstellung eines Arzneimittels zur Behandlung von Drogenabhängigkeit und Entzugserscheinungen | |
| Sparkes et al. | Assessment of adrenal function in cats: response to intravenous synthetic ACTH | |
| EP3199156A1 (de) | Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika | |
| DE3937340A1 (de) | Verfahren zur erzeugung von analgesie bei saeugern | |
| Duce et al. | Experimental epidural anaesthesia in the cat with lignocaine and amethocaine | |
| DE202006018609U1 (de) | Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung | |
| DE69529819T2 (de) | Neue kombination eines betablockers mit einem lokalanästhetikum | |
| DE3602370A1 (de) | Verwendung von analgetica durch inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8380 | Miscellaneous part iii |
Free format text: DER PATENTINHABER LAUTET RICHTIG: BAKER NORTON PHARMACENTICALS INC., MIAMI, FLA., US |
|
| 8364 | No opposition during term of opposition |